Recce Pharmaceuticals Ltd.ASX: RCE

Safety Committee Approves Expansion of Ph I/II DFI Trial

· Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Recce Pharmaceuticals Ltd. announced that an Independent Safety Committee has approved the expansion of its Phase I/II clinical trial for a treatment of diabetic foot infections, confirming the trial is safe and effective. The trial is achieving its primary endpoints of safety, tolerability, and efficacy, with plans to launch additional clinical sites in Australia and internationally.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Recce Pharmaceuticals Ltd. on 6ix

Story so far

Earlier from Recce Pharmaceuticals

Later from Recce Pharmaceuticals

All Recce Pharmaceuticals news releases